Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829049 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
A Phase 4 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 165
- Enrollment target
NCT00829049 is a Phase 4 study that was terminated before completion, run by Allergan. The registered enrollment target is 165 participants.
The verdict
NCT00829049, a Phase 4 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 165 participants
- Enrollment target
Study Summary
Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
Interventions
- DRUG Adapalene
- DRUG Tazarotene Cream 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829049
The ClinicalTrials.gov registry entry for NCT00829049 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adapalene is the first listed.
NCT00829049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829049 about?
NCT00829049 is a clinical study titled "Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris". Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
What is the current status of trial NCT00829049?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 165 participants. The study started on 2007-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00829049?
The interventions under investigation include: Adapalene (DRUG), Tazarotene Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT00829049?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.